Topics:

Atrial Fibrillation

It has long been understood that MI may increase the risk of atrial fibrillation. A study in JAMA-Internal Medicine now finds that that the opposite relationship may also be true.

 

Atrial Fibrillation

A small study provides good evidence that radiofrequency ablation as first-line therapy has a lower failure rate vis a vis recurrence of AF when compared with antiarrhythmic therapy. But, there is more to this story.

According to a study published in the British Medical Journal, the risk of atrial fibrillation/atrial flutter is greater in NSAID-naive patients than in those with previous exposure.

Four updates to the guidelines are important for primary care physicians to review.

In clinical scenarios where warfarin is still the drug of choice for anticoagulation, it is still a challenge to achieve optimal time in therapeutic range. Is there promise in a new dosing paradigm?

Results of a new study suggest that number of LAA lobes may one day be useful as an element of the CHADS2 scoring system for embolic risk in patients with atrial fibrillation.

Comprising 15,400 patients from 46 countries, the RE-LY AF registry offers a notable opportunity to study variations in presentation of atrial fibrillation and its risk factors.

In dialysis patients, anticoagulation for AF may be cause for clinical equipoise, regardless of bleeding risk score. New research, reported here, may begin to shift the balance.

Pages

Subscribe to
Please Wait 20 seconds or click here to close